01 5Seretide/Advair
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,128
2019 Revenue in Millions : 2,398
Growth (%) : -11
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,836
2020 Revenue in Millions : 2,103
Growth (%) : -12
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 1,429
2021 Revenue in Millions : 1,836
Growth (%) : -22
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 1,229
2022 Revenue in Millions : 1,429
Growth (%) : -2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 2,145
2018 Revenue in Millions : 3,003
Growth (%) : -29
LOOKING FOR A SUPPLIER?